Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Shares Purchased by Atlas Capital Advisors Inc.

Key Points

• Atlas Capital Advisors Inc. significantly increased its stake in Jazz Pharmaceuticals PLC by 1,378.8%, now holding shares valued at $573,000 after acquiring 4,302 additional shares in the first quarter.
• Several hedge funds, including LPL Financial LLC and Envestnet Asset Management Inc., have also increased their positions in Jazz Pharmaceuticals, contributing to institutional investors owning 89.14% of the stock.
• Analysts' ratings for Jazz Pharmaceuticals vary, with an average rating of "Moderate Buy" and a range of target prices, while the company's stock is currently trading at approximately $111.30.

Atlas Capital Advisors Inc. grew its holdings in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) by 1,378.8% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm owned 4,614 shares of the specialty pharmaceutical company's stock after buying an additional 4,302 shares during the period. Atlas Capital Advisors Inc.'s holdings in Jazz Pharmaceuticals were worth $573,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. Focus Partners Wealth purchased a new position in shares of Jazz Pharmaceuticals in the 4th quarter valued at approximately $551,000. CX Institutional purchased a new position in shares of Jazz Pharmaceuticals in the 1st quarter valued at approximately $4,316,000. Envestnet Portfolio Solutions Inc. lifted its stake in shares of Jazz Pharmaceuticals by 38.9% in the 1st quarter. Envestnet Portfolio Solutions Inc. now owns 4,369 shares of the specialty pharmaceutical company's stock valued at $542,000 after purchasing an additional 1,223 shares during the period. GAMMA Investing LLC lifted its stake in shares of Jazz Pharmaceuticals by 63.7% in the 1st quarter. GAMMA Investing LLC now owns 1,015 shares of the specialty pharmaceutical company's stock valued at $126,000 after purchasing an additional 395 shares during the period. Finally, Janney Montgomery Scott LLC purchased a new position in shares of Jazz Pharmaceuticals in the 1st quarter valued at approximately $1,888,000. 89.14% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Jazz Pharmaceuticals

In related news, CEO Bruce C. Cozadd sold 1,000 shares of the stock in a transaction that occurred on Tuesday, July 1st. The stock was sold at an average price of $107.63, for a total value of $107,630.00. Following the transaction, the chief executive officer owned 436,973 shares of the company's stock, valued at $47,031,403.99. This represents a 0.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 4.30% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of brokerages have issued reports on JAZZ. Deutsche Bank Aktiengesellschaft initiated coverage on Jazz Pharmaceuticals in a research note on Tuesday, July 15th. They set a "buy" rating and a $152.00 price objective for the company. Piper Sandler restated an "overweight" rating and set a $147.00 price objective (down from $176.00) on shares of Jazz Pharmaceuticals in a research note on Wednesday, May 7th. Morgan Stanley cut their price target on shares of Jazz Pharmaceuticals from $165.00 to $162.00 and set an "overweight" rating on the stock in a report on Wednesday, August 6th. Needham & Company LLC restated a "buy" rating and issued a $202.00 price objective on shares of Jazz Pharmaceuticals in a report on Wednesday, June 11th. Finally, Robert W. Baird lowered their price objective on Jazz Pharmaceuticals from $167.00 to $155.00 and set an "outperform" rating on the stock in a research report on Wednesday, May 7th. Two analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $181.43.

Jazz Pharmaceuticals Price Performance

Shares of NASDAQ:JAZZ traded up $2.58 during mid-day trading on Tuesday, reaching $113.33. The stock had a trading volume of 772,582 shares, compared to its average volume of 801,574. The company has a current ratio of 1.62, a quick ratio of 1.37 and a debt-to-equity ratio of 1.17. The company has a market cap of $6.87 billion, a P/E ratio of -16.84, a price-to-earnings-growth ratio of 7.12 and a beta of 0.34. Jazz Pharmaceuticals PLC has a 1 year low of $95.49 and a 1 year high of $148.06. The business's 50 day moving average price is $111.38 and its 200 day moving average price is $117.37.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) EPS for the quarter, missing analysts' consensus estimates of ($5.61) by ($2.64). The firm had revenue of $1.05 billion for the quarter, compared to analysts' expectations of $1.05 billion. Jazz Pharmaceuticals had a positive return on equity of 5.02% and a negative net margin of 9.91%. Jazz Pharmaceuticals's revenue for the quarter was up 2.1% on a year-over-year basis. During the same period in the prior year, the firm posted $5.30 earnings per share. Research analysts expect that Jazz Pharmaceuticals PLC will post 16.96 EPS for the current fiscal year.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.